NYSE · CSPCY
Healthcare · Drug Manufacturers - General
$4.39
Up+$0.00 (+0.00%)
Updated Aug 24, 2026, 3:26 PM
SID Score
5.9/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CSPCY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CSPCY.
CSPCY research
Company profile and research snapshot.
CSPC PHARMS GRP U/ADR
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Jan 5, 2026
Novo Nordisk A/S rated Buy: FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as compared to LLY.
defenseworld.net · Dec 12, 2025
CSPC Pharmaceutical Group Limited (OTCMKTS:CSPCY - Get Free Report)'s share price traded down 0.5% during trading on Thursday. The company traded as low as C$3.88 and last traded at C$3.91. 35,649 shares were traded during mid-day trading, an increase of 58% from the average session volume of 22,493 shares. The stock had previously closed
Yahoo · Nov 25, 2025
Find insight on Novo Nordisk, CSPC Pharmaceutical Group and more in the latest Market Talks covering Health Care.
GlobeNewswire Inc. · Nov 10, 2025
Madrigal Pharmaceuticals presented two-year data on Rezdiffra, demonstrating significant improvements in liver imaging tests and biomarkers for patients with compensated MASH cirrhosis, highlighting potential benefits across different patient populations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CSPCY.
